Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs
スポンサーリンク
概要
- 論文の詳細を見る
- 2001-12-01
著者
-
KOJIMA Junji
興和株式会社東京研究所
-
Kojima Junji
Tokyo New Drug Research Laboratories Kowa Company Ltd.
-
Kojima Junji
興和株式会社 東京研究所
-
OHSHIMA Takeshi
興和株式会社 東京研究所
-
YONEDA Michiaki
興和株式会社 東京研究所
-
SAWADA Hironobu
興和株式会社 東京研究所
関連論文
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (4) : Interspecies Variation in Laboratory Animals and Humans
- Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs
- Uptake Mechanism of Pitavastatin, a New Inhibitor of HMG-CoA Reductase, in Rat Hepatocytes
- Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase : Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr1a/b Gene Disruption on Tissue Distribution in Mice
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reduetase (5) : In Vitro Metabolism and Plasma Protein Binding in Animals and Human
- Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
- Identification of Metabolites of NK-104,an HMG-CoA Reductase Inhibitor, in Rat, Rabbit and Dog Bile
- PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. I. STUDIES ON INTERSPECIES VARIATION IN LABORATORY ANIMALS
- PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. II. INFLUENCE OF THE ROUTE OF ADMINISTRATION ON BIOAVAILABILITY IN DOGS
- Studies on metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase-Does glucronidation mediate the lactonization of pitavastatin?
- Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase
- Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent, in human.